PepGen, Inc. (NASDAQ:PEPG) Receives $11.50 Consensus PT from Analysts

Shares of PepGen, Inc. (NASDAQ:PEPG) have received an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $11.50.

Several research analysts have recently weighed in on the stock. Wedbush reduced their price target on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. Craig Hallum initiated coverage on shares of PepGen in a research report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 price objective on the stock. Weiss Ratings lowered shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. HC Wainwright reiterated a “buy” rating on shares of PepGen in a report on Thursday, May 21st. Finally, Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Sunday, June 7th.

PepGen Price Performance

NASDAQ:PEPG opened at $1.83 on Wednesday. The business’s 50-day simple moving average is $1.78 and its 200-day simple moving average is $3.31. PepGen has a fifty-two week low of $1.01 and a fifty-two week high of $7.80. The stock has a market capitalization of $126.58 million, a PE ratio of -1.05 and a beta of 1.88.

PepGen (NASDAQ:PEPG) last posted its earnings results on Tuesday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. On average, research analysts expect that PepGen will post -1.2 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PEPG. RA Capital Management L.P. lifted its stake in PepGen by 87.7% in the 3rd quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock valued at $92,698,000 after acquiring an additional 9,375,000 shares in the last quarter. Commodore Capital LP boosted its position in PepGen by 31.6% during the 1st quarter. Commodore Capital LP now owns 4,475,000 shares of the company’s stock worth $7,921,000 after acquiring an additional 1,075,000 shares during the last quarter. Viking Global Investors LP grew its stake in shares of PepGen by 134.9% during the 3rd quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock worth $16,089,000 after acquiring an additional 2,000,000 shares in the last quarter. Vivo Capital LLC bought a new position in shares of PepGen during the 3rd quarter worth approximately $10,742,000. Finally, Laurion Capital Management LP grew its stake in shares of PepGen by 8.5% during the 4th quarter. Laurion Capital Management LP now owns 2,052,133 shares of the company’s stock worth $13,359,000 after acquiring an additional 159,977 shares in the last quarter. 58.01% of the stock is currently owned by institutional investors.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).